Publisher Correction: Toripalimab or placebo plus chemotherapy as first-line treatment in advanced nasopharyngeal carcinoma: a multicenter randomized phase 3 trial (Nature Medicine, (2021), 27, 9, (1536-1543), 10.1038/s41591-021-01444-0)

Hai Qiang Mai, Qiu Yan Chen, Dongping Chen, Chaosu Hu, Kunyu Yang, Jiyu Wen, Jingao Li, Ying Rui Shi, Feng Jin, Ruilian Xu, Jianji Pan, Shenhong Qu, Ping Li, Chunhong Hu, Yi Chun Liu, Yi Jiang, Xia He, Hung Ming Wang, Wan Teck Lim, Wangjun LiaoXiaohui He, Xiaozhong Chen, Zhigang Liu, Xianglin Yuan, Qi Li, Xiaoyan Lin, Shanghua Jing, Yanju Chen, Yin Lu, Ching Yun Hsieh, Muh Hwa Yang, Chia Jui Yen, Jens Samol, Hui Feng, Sheng Yao, Patricia Keegan, Rui Hua Xu*

*此作品的通信作者

研究成果: Comment/debate

2 引文 斯高帕斯(Scopus)

摘要

In the version of this article initially published, there were textual errors in the abstract and main text. In the penultimate sentence of the abstract, the text “immune-related AEs (irAEs) (39.7 versus 18.9%) and grade ≥3 irAEs (7.5 versus 0.7%)” now replaces “immune-related AEs (39.7 versus 18.9%) and grade ≥3 infusion reactions (7.5 versus 0.7%).” In the third paragraph of the “Adverse events” subsection, first sentence, the text “infusion reactions (4.1 versus 4.2%) was similar in the two arms (Supplementary Tables 19-22). In contrast, irAEs as assessed by the investigator” now replaces “infusion reactions (irAEs) (4.1 versus 4.2%) was similar in the two arms (Supplementary Tables 19-22). In contrast, immune-related adverse events.” Further, in Table 2, bottom row “P value” entry, footnote “b” replaces “a”, and in the footnote legend, “a” replaces “*” and “b” replaces “a.” The changes have been made in the online version of the article.

原文English
期刊Nature Medicine
DOIs
出版狀態Accepted/In press - 2022

指紋

深入研究「Publisher Correction: Toripalimab or placebo plus chemotherapy as first-line treatment in advanced nasopharyngeal carcinoma: a multicenter randomized phase 3 trial (Nature Medicine, (2021), 27, 9, (1536-1543), 10.1038/s41591-021-01444-0)」主題。共同形成了獨特的指紋。

引用此